What is Thymalin 50MG

Thymalin 50MG is a purified polypeptide complex extracted from the thymus gland of young calves, studied in research for its broad, foundational immunomodulatory effects. It is intended exclusively for research use.

Regarding its chemical identity, Thymalin has a molecular formula of Complex Polypeptide Extract and a molecular weight of < 10,000 g/mol. Its reported canonical sequence is N/A (Complex Mixture). A confirmed CAS number is not available in open primary reference sources and is therefore omitted.

Its synonyms include Thymalin.

Product for research use.

Mechanism of action of Thymalin

Thymalin restores the functional capacity of the immune system by directly regulating the ratio of T-cell and B-cell subpopulations. It enhances phagocytosis, stimulates the production of endogenous interferons, and normalizes cellular immunity during severe immunodeficiency.

Pharmacokinetics and pharmacodynamics of Thymalin

As a complex extract containing multiple active peptides, its pharmacokinetics are broad. It acts systemically to reset the entire immune cascade, with its regulatory effects lasting significantly longer than the clearance time of the individual peptides.

Scientific evidence on Thymalin

The available evidence on Thymalin is preliminary and largely inconclusive, and should be interpreted with caution. The literature describes it as having been investigated for multiple indications in preclinical models.

Extensively documented in Russian clinical medicine for the treatment of acute and chronic infections, post-operative immune suppression, and adjunctive cancer therapy. Preclinical models show it accelerates recovery from severe immunosuppressive trauma.

Thymalin applications in research

Ideal for (research context):
– In vitro and preclinical studies of its specific receptor pathways.
– Investigation of tissue repair, cell proliferation, and functional restoration in laboratory models.
– Comparative work with related peptides.

Not applicable for:
– clinical, diagnostic or therapeutic use.
– Any administration to humans or animals outside of an authorized research protocol.

Product for research use.

Thymalin protocols in preclinical studies

The literature consulted does not include numerical doses from studies that can be cited for Thymalin, so no trial schemes or quantities are specified.

The presentations of this product (50MG) refer only to the amount of lyophilized peptide per vial (or volume for liquids) and do not constitute a dosage recommendation. The design of any protocol, including concentrations and working volumes, is the responsibility of the researcher, based on their experimental objectives and the relevant primary literature.

Information provided exclusively for research purposes.

Reconstitution and manipulation of Thymalin

As a general guideline for laboratory handling, lyophilized peptides such as Thymalin are usually reconstituted with bacteriostatic water (sterile water with approximately 0.9% benzyl alcohol).

Add the solvent slowly down the side of the vial, letting it run over the lyophilized powder; avoid injecting the stream directly onto the powder.
Do not shake: gently rotate the vial until completely dissolved.
Adjust the solvent volume according to the desired working concentration, considering the 50MG contents of the vial.

These guidelines are for general technique and do not replace the internal procedures of each laboratory.

Thymalin Stability and Storage

As a standard laboratory handling procedure for peptides:

Freeze-dried (unreconstituted): This is the most stable form. It is best preserved by freezing and protecting it from moisture and light for long-term storage.
Reconstituted: once in solution, the peptide is less stable and must be kept refrigerated, being used within a short period; for extended storage, freezing in aliquots is usually preferred.
Avoid repeated freeze-thaw cycles, as they can degrade the peptide.

Given that the molecule is characterized by rapid enzymatic degradation in biological media, careful cold chain management is especially relevant.

Documented Thymalin security profile

The documented safety information in open sources for Thymalin is limited and should be interpreted with caution, also considering that it is research material and not for clinical use.

Derived from animal sources, there is a theoretical risk of allergic or autoimmune reactions, though modern purification drastically reduces this. It does not cause the severe toxicity associated with systemic corticosteroids or chemotherapies.

Formal contraindications and adverse event rates are not available in the consulted literature, so no figures are reported.

Thymalin in a comparative context

Compared to Thymosin Alpha-1 (a single, synthetic peptide), Thymalin is a complex, multi-peptide extract that provides a broader, more holistic resetting of the thymus gland. It is the natural precursor to synthetic cytogens like Crystagen and Vilon.

History and development of Thymalin

Developed in the Soviet Union during the 1970s as a foundational treatment for immunosenescence and radiation-induced immune damage. It remains a cornerstone of Russian immunomodulatory therapy and bioregulator research.